References

Chronic kidney disease.

10.1038/s41572-024-00589-9 · 2025 · External reference

Cardiovascular outcomes in patients with diabetes and kidney disease: JACC review topic of the week.

10.1016/j.jacc.2023.04.052 · 2023 · External reference

Acute kidney injury.

10.1016/s0140-6736(24)02385-7 · 2025 · External reference

Timing of cardio-kidney protection with SGLT2 inhibitors: insights from 4 large-scale placebo-controlled outcome trials.

10.1161/circulationaha.124.069382 · 2024 · External reference

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.

10.1016/s2213-8587(23)00321-2 · 2024 · External reference

Albuminuria in cardiovascular, kidney, and metabolic disorders: a state-of-the-art review.

10.1161/circulationaha.124.071079 · 2025 · External reference

Prescription patterns for sodium-glucose cotransporter 2 inhibitors in U.S. health systems.

10.1016/j.jacc.2024.05.057 · 2024 · External reference

Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations.

10.1016/j.jacc.2023.04.034 · 2023 · External reference

SGLT2 inhibitors in patients with heart failure and chronic kidney disease: jigsaw falling into place.

10.1016/j.jacc.2023.03.389 · 2023 · External reference

Dapagliflozin in patients with heart failure and deterioration in renal function.

10.1016/j.jacc.2023.08.026 · 2023 · External reference

Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes.

10.1056/nejmoa2410659 · 2025 · External reference

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.

10.1038/s41591-024-03133-0 · 2024 · External reference

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.

10.1038/ki.2013.356 · 2014 · External reference

Influence of renal function on the 52-week efficacy and safety of the sodium glucose cotransporter 2 inhibitor luseogliflozin in japanese patients with type 2 diabetes mellitus.

10.1016/j.clinthera.2015.10.025 · 2016 · External reference

Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study.

10.1007/s13300-017-0337-5 · 2018 · External reference

Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus.

10.2337/dc19-0093 · 2019 · External reference

Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.

10.1111/dom.12428 · 2015 · External reference

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.

10.1111/dom.12348 · 2014 · External reference

Quételet (body mass) index and effects of dapagliflozin in chronic kidney disease.

10.1111/dom.14641 · 2022 · External reference

Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: a randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY).

10.1111/dom.15249 · 2023 · External reference

A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study.

10.1111/dom.12403 · 2015 · External reference

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE Study.

10.1111/dom.13413 · 2018 · External reference

Empagliflozin in patients with chronic kidney disease.

10.1056/nejmoa2204233 · 2023 · External reference

Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease.

10.1093/ndt/gfaf046 · 2025 · External reference

Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.

10.1093/ndt/gfx350 · 2018 · External reference

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.

10.1093/ndt/gfz290 · 2020 · External reference

Sotagliflozin in patients with diabetes and chronic kidney disease.

10.1056/nejmoa2030186 · 2021 · External reference

Safety and effectiveness of bexagliflozin in patients with type 2 diabetes mellitus and stage 3a/3b CKD.

10.1053/j.ajkd.2019.03.417 · 2019 · External reference

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.

10.1016/s2213-8587(20)30369-7 · 2021 · External reference

Efficacy and safety of dapagliflozin in patients with acute heart failure.

10.1016/j.jacc.2024.02.009 · 2024 · External reference

Metabolic communication by SGLT2 inhibition.

10.1161/circulationaha.123.065517 · 2024 · External reference

Kidney and cardiovascular effectiveness of SGLT2 inhibitors vs GLP-1 receptor agonists in type 2 diabetes.

10.1016/j.jacc.2024.06.016 · 2024 · External reference

Prevention of cardiorenal complications in people with type 2 diabetes and obesity.

10.1016/j.cmet.2023.12.018 · 2024 · External reference

GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type 2 diabetes.

10.1016/j.jacc.2023.05.048 · 2023 · External reference

SGLT2 inhibitors in clinical practice.

10.1016/s2213-8587(24)00133-5 · 2024 · External reference

Innovative therapeutics for renoprotection: where we are.

10.1016/j.pharmr.2025.100060 · 2025 · External reference

Rethinking eGFR comparisons in SGLT2 inhibitor research.

10.1016/j.jacc.2023.09.838 · 2024 · External reference